Higher Heart Rate After Heart Attack Signals Greater Risk Even in Modern Care
New analysis of 3,698 post-MI patients shows elevated heart rate predicts worse outcomes, and stopping beta-blockers raises HR by 10–13 bpm.
Summary
A major new analysis from the ABYSS trial tracked over 3,600 patients who had experienced a heart attack with preserved heart function. Researchers found that those with higher resting heart rates—68 bpm or above—had a 55% higher risk of death, another heart attack, or stroke compared to those under 60 bpm. Importantly, patients who stopped taking beta-blockers saw their heart rate rise by roughly 10–13 beats per minute, and this was consistently linked with worse outcomes regardless of their starting heart rate. The findings reinforce that heart rate remains a meaningful risk marker after heart attack even in today's era of advanced reperfusion techniques, and that beta-blocker therapy should generally be continued in stable post-MI patients with preserved ejection fraction.
Detailed Summary
Heart rate has long been considered a marker of cardiovascular risk, but its relevance after myocardial infarction in the modern reperfusion era—where most patients are rapidly treated with stenting or clot-dissolving therapy—has been questioned. This new analysis from the ABYSS trial directly addresses that uncertainty.
Researchers conducted a prespecified secondary analysis of 3,698 stable post-MI patients with preserved left ventricular ejection fraction (≥40%) who were randomized to either continue or discontinue beta-blocker therapy approximately one year after their heart attack. Patients were divided into three heart rate groups at the time of randomization: below 60 bpm, 60–67 bpm, and 68 bpm or higher.
The results were striking. While baseline heart rate was not associated with the composite primary endpoint overall, higher heart rate was significantly linked to harder outcomes. Patients in the highest tertile (≥68 bpm) had a 55% increased adjusted risk of death, recurrent MI, or stroke compared to the lowest tertile. All-cause mortality also rose steadily across groups—from 2.9% to 3.4% to 5.9%. When beta-blockers were stopped, heart rate increased by approximately 10–13 bpm during follow-up, and this interruption was consistently associated with worse cardiovascular outcomes across all heart rate categories and ejection fraction ranges.
For clinicians, the message is clear: resting heart rate remains a clinically meaningful prognostic signal in stabilized post-MI patients, and beta-blocker discontinuation carries real risk regardless of where a patient's baseline heart rate falls. This supports current guidelines recommending beta-blocker continuation post-MI.
Caveats apply. This is a secondary analysis of a randomized trial, meaning causality between heart rate elevation and outcomes cannot be fully established. Summary is based on the abstract only, so full methodological details and subgroup analyses are unavailable.
Key Findings
- Post-MI patients with resting HR ≥68 bpm had a 55% higher adjusted risk of death, MI, or stroke vs. those under 60 bpm.
- All-cause mortality nearly doubled from lowest to highest heart rate tertile (2.9% vs. 5.9%).
- Stopping beta-blockers raised heart rate by 10–13 bpm during follow-up in a dose-dependent fashion.
- Beta-blocker interruption was linked to worse outcomes regardless of baseline heart rate or ejection fraction category.
- Heart rate remains a prognostically meaningful biomarker after MI even in the modern reperfusion era.
Methodology
This was a prespecified secondary analysis of the ABYSS randomized controlled trial involving 3,698 stable post-MI patients with LVEF ≥40%, randomized to continue or interrupt beta-blocker therapy about one year post-MI. Patients were stratified by prerandomization heart rate tertiles and followed for the composite endpoint of death, MI, stroke, or cardiovascular rehospitalization. Cox regression models adjusted for relevant covariates were used to assess associations.
Study Limitations
This is a secondary analysis of a randomized trial, which limits causal interpretation of the heart rate–outcome relationship. The summary is based on the abstract only, so full covariate adjustment details, subgroup breakdowns, and sensitivity analyses are unavailable. The study population was predominantly male (83%) and excluded patients with LVEF <40%, limiting generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.